
Going forward, Biogen and Eisai won’t be splitting global profits of Alzheimer’s drug Aduhelm (aducanumab), which is marketed in the US under the brand name Aduhelm, the companies announce in separate press releases.
Rather, Eisai will begin receiving tiered royalties based on net sales of the drug, which will take effect Jan. 1, 2023.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app